Id: acc1778
Group: 2sens
Protein: GPNMB
Gene Symbol: GPNMB
Protein Id: Q14956
Protein Name: GPNMB_HUMAN
PTM: glycosylation
Site: Asn134
Site Sequence: GLSADPYVYNWTAWSEDSDGE
Disease Category: Cancer
Disease: Lung Cancer
Disease Subtype: NSCLC
Disease Cellline: H1299
Disease Info:
Drug: -
Drug Info: -
Effect: resist
Effect Info: "Glycosylation at the N134 site of GPNMB plays a crucial role in this regulation. Removal of N134 glycosylation can significantly inhibit the binding of GPNMB to mutant EGFR and its downstream signaling, ultimately suppressing the metastasis of NSCLC."
Note: no drug
Score: 3.0
Pubmed(PMID): 33706413
Sentence Index:
Sentence:

Sequence & Structure:

MECLYYFLGFLLLAARLPLDAAKRFHDVLGNERPSAYMREHNQLNGWSSDENDWNEKLYPVWKRGDMRWKNSWKGGRVQAVLTSDSPALVGSNITFAVNLIFPRCQKEDANGNIVYEKNCRNEAGLSADPYVYNWTAWSEDSDGENGTGQSHHNVFPDGKPFPHHPGWRRWNFIYVFHTLGQYFQKLGRCSVRVSVNTANVTLGPQLMEVTVYRRHGRAYVPIAQVKDVYVVTDQIPVFVTMFQKNDRNSSDETFLKDLPIMFDVLIHDPSHFLNYSTINYKWSFGDNTGLFVSTNHTVNHTYVLNGTFSLNLTVKAAAPGPCPPPPPPPRPSKPTPSLATTLKSYDSNTPGPAGDNPLELSRIPDENCQINRYGHFQATITIVEGILEVNIIQMTDVLMPVPWPESSLIDFVVTCQGSIPTEVCTIISDPTCEITQNTVCSPVDVDEMCLLTVRRTFNGSGTYCVNLTLGDDTSLALTSTLISVPDRDPASPLRMANSALISVGCLAIFVTVISLLVYKKHKEYNPIENSPGNVVRSKGLSVFLNRAKAVFFPGNQEKDPLLKNQEFKGVS

No data.

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
GPNMB GLEMBATUMUMAB VEDOTIN Transmembrane glycoprotein NMB binding agent 2 Completed osteosarcoma ClinicalTrials
GPNMB GLEMBATUMUMAB VEDOTIN Transmembrane glycoprotein NMB binding agent 2 Terminated melanoma ClinicalTrials
GPNMB GLEMBATUMUMAB VEDOTIN Transmembrane glycoprotein NMB binding agent 2 Completed Uveal Melanoma ClinicalTrials
GPNMB GLEMBATUMUMAB VEDOTIN Transmembrane glycoprotein NMB binding agent 2 Completed breast cancer ClinicalTrials
ClinicalTrials
GPNMB GLEMBATUMUMAB VEDOTIN Transmembrane glycoprotein NMB binding agent 1 Terminated squamous cell lung carcinoma ClinicalTrials
GPNMB GLEMBATUMUMAB Transmembrane glycoprotein NMB binding agent 1 Completed melanoma ClinicalTrials
GPNMB GLEMBATUMUMAB Transmembrane glycoprotein NMB binding agent 1 Completed breast cancer ClinicalTrials
GPNMB GLEMBATUMUMAB VEDOTIN Transmembrane glycoprotein NMB binding agent 0.5 Withdrawn breast cancer ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No data.

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
N 134 U Non-small cell lung cancer Glycosylation 33706413

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: